ESPE Abstracts (2021) 94 P2-6

ESPE2021 ePoster Category 2 Adrenals and HPA Axis (57 abstracts)

Single centre experience of Hydrocortisone Granules (Alkindi) in children under 6 years of age with Adrenal Insufficiency

Claire Snow & Catherine Owen

28 views


Department of Paediatric Endocrinology, Great North Children’s Hospital, Newcastle upon Tyne, United Kingdom


Introduction: Children with Adrenal insufficiency (AI) are usually managed with glucocorticoid replacement as hydrocortisone. Treatment options in younger patients include administering an aliquot of 10mg hydrocortisone tablets dissolved in water. However, this is time consuming and may be inaccurate. We describe our experience of using Alkindi (www.diurnal.co.uk), the first hydrocortisone preparation licensed for children with AI.

Method: Thirty-one patients with AI (24M, 7F) under 6-years of age in our service were identified over a 30 month period. 18 were diagnosed with congenital adrenal hyperplasia, 11 combined pituitary hormone deficiency and 2 neonatal adrenal haemorrhage. 22 were on hydrocortisone preparations already and 9 were started on Alkindi at the time of diagnosis. Data on growth, episodes of stress dosing and adrenal crisis were documented at clinic visits and a questionnaire captured caregivers experience with their current regimen, with stress-dose information focused around the last 6-months.

Results: The 9 newly-diagnosed patients started directly onto Alkindi all remain on this preparation. 20 of the 22 patients on hydrocortisone ‘tablet solution’ were switched to Alkindi- 15 (75%) remain on Alkindi 23-30 months later, tolerating and preferring this treatment; 5 (25%) did not tolerate Alkindi and returned to dissolving tablets. In the most recent 6-months, stress dosing varied from 0-4 occasions, with an average of 2.8 episodes per patient per year and with no significant difference between preparations. No patient was admitted with an adrenal crisis. For patients switched to Alkindi (n = 15), the height SDS moved closer to the population average after 1-year on Alkindi (mean height SDS pre-treatment -0.42; 1-year post-treatment -0.19). The heights of 12/14 patients were closer to the mid-parental target SDS (0.13). For those starting Alkindi at diagnosis (n = 9), height SDS also moved closer to the population average (mean height SDS pre-treatment -1.52; 1-year post-treatment -0.15) and mid-parental height SDS (0.58). E-mail questionnaires were sent to 27 patients and 23 responded. All were satisfied (38% HC; 27% Alkindi) or very satisfied (62% HC; 73% Alkindi) with their current hydrocortisone preparation.

Conclusions: This is the largest single centre report of Alkindi administration over the longest time-period. All newly treated patients remained on Alkindi, although 25% of families who transitioned to Alkindi opted to return to dissolving tablets. There was high patient satisfaction irrespective of the underlying preparation, with no safety issues highlighted and in particular no adrenal crises. Growth parameters were encouraging, with no evidence of toxicity based on height SDS scores.

Volume 94

59th Annual ESPE (ESPE 2021 Online)

Online,
22 Sep 2021 - 26 Sep 2021

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.